Drugs / FL115
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07131189 | May 2024 → Jun 2026 overdue | — | Suzhou Forlong Biotechnology Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06130722 | Dec 2023 → Feb 2025 | RET fusion positive cancer | Suzhou Forlong Biotechnology Co., Ltd | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07131202 | Jan → Dec 2026 expected | cancer | Suzhou Forlong Biotechnology Co., Ltd | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07122414 | Aug 2024 → Oct 2027 expected | urinary bladder carcinoma | Suzhou Forlong Biotechnology Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FL115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07131189 ↗ |
| Action | Activate | “IL-15 agonist” NCT06130722 ↗ |
| Modality | Protein / enzyme biologic | “fusion protein” NCT06130722 ↗ |
| Route | Intravenous | “when administered IV” NCT06130722 ↗ |